Compare PTGX & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTGX | RDY |
|---|---|---|
| Founded | 2006 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 9.9B |
| IPO Year | 2016 | 2001 |
| Metric | PTGX | RDY |
|---|---|---|
| Price | $139.40 | $12.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 5 |
| Target Price | ★ $174.69 | $13.31 |
| AVG Volume (30 Days) | 535.2K | ★ 2.5M |
| Earning Date | 11-05-2026 | 10-23-2026 |
| Dividend Yield | N/A | ★ 0.51% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.35 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,078.44 | $4.73 |
| Revenue Next Year | N/A | $11.63 |
| P/E Ratio | $60.03 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $62.24 | $11.36 |
| 52 Week High | $160.81 | $15.67 |
| Indicator | PTGX | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 54.62 |
| Support Level | $132.37 | $12.09 |
| Resistance Level | $142.20 | $12.48 |
| Average True Range (ATR) | 4.59 | 0.21 |
| MACD | -0.44 | 0.07 |
| Stochastic Oscillator | 39.61 | 64.87 |
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.